Vaxess Technologies Announces Grand Opening of GMP Manufacturing Facility
Vaxess Technologies celebrates the grand opening of their 3,600 square feet pilot GMP manufacturing facility on Monday.
Vaxess Technologies celebrates the grand opening of their 3,600 square feet pilot GMP manufacturing facility on Monday.
The study demonstrates that the new plant system for norovirus vaccine production is effective against the tenacious pathogen and that the versatile method could be used for the development of a broad range of novel vaccines. It is estimated that an effective vaccine against gastroenteritis could save billions of dollars in healthcare costs in the U.S. alone.